Glycotope and Evotec enter licensing agreement to combine Glycotope antibodies and Evotec’s immune cell engager platform
December 11, 2023 02:00 ET
|
Glycotope
Glycotope and Evotec enter licensing agreement to combine Glycotope antibodies and Evotec’s immune cell engager platform Berlin, Germany, 11 December 2023 – Glycotope GmbH (Glycotope) has signed...
SLRN Investor Alert: Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN)
December 07, 2023 08:00 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased Acelyrin, Inc.
Rentschler Biopharma SE appoints Gunnar Voss von Dahlen as Chief Financial Officer and completes Executive Board
December 07, 2023 04:00 ET
|
Rentschler Biopharma SE
LAUPHEIM, Germany and MILFORD, Mass. and STEVENAGE, United Kingdom, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Rentschler Biopharma SE, a leading contract development and manufacturing organization (CDMO)...
Re:Dish Secures Spot on Inc.'s 2023 Best in Business List By Eliminating Nearly 2 Million Single-Use Packaging Items in First Full Year of Operation
December 05, 2023 10:48 ET
|
Re:Dish Co.
Re:Dish Secures Spot on Inc.'s 2023 Best in Business List By Eliminating Nearly 2 Million Single-Use Packaging Items in First Full Year of Operation
First Wave BioPharma CEO James Sapirstein to Moderate Panel Discussion at Longwood Healthcare Leaders Conference
December 05, 2023 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Dec. 05, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Polaris Group Initiates Phase 3 Trial: First Patient Successfully Dosed with ADI-PEG 20/Placebo plus Gemcitabine and Docetaxel for Difficult-to-Treat Leiomyosarcoma (LMS)
December 04, 2023 07:00 ET
|
Polaris Group
TAIPEI, Taiwan and SAN DIEGO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Polaris Group (The Company, TWSE:6550), today announced that the first patient is successfully dosed in a pivotal Phase 3 trial that...
Monthly information on share capital and company voting rights
December 01, 2023 16:30 ET
|
Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 ...
Particle Size Analysis Market worth $596 million | MarketsandMarkets.
November 30, 2023 07:30 ET
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Particle Size Analysis Market in terms of revenue was estimated to be worth $446 million in 2023 and is poised to reach $596 million by 2028, growing at a...
Polaris Group Announces First Patient Successfully Dosed with ADI-PEG 20/Placebo in Phase 2a Non-Alcoholic Steatohepatitis (NASH) Study
November 29, 2023 19:59 ET
|
Polaris Group
TAIPEI, Taiwan and SAN DIEGO, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Polaris Group (The Company, TWSE:6550), today announced that the first patient was successfully dosed in the Phase 2a clinical study...
Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN)
November 28, 2023 13:44 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased Acelyrin, Inc. (Nasdaq: SLRN) common stock.